Literature DB >> 28943946

Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer.

Libo Si1, Hui Tian1, Weiming Yue1, Lin Li1, Shuhai Li1, Cun Gao1, Lei Qi1.   

Abstract

MicroRNAs (miRNAs/miRs) are a class of small, highly conserved non-coding RNAs that can serve either oncogenic or tumor-suppressive roles in a wide variety of tumors. miR-200c is a member of the miR-200 family whose specific role in non-small cell lung cancer (NSCLC) has not yet been elucidated. The purpose of the present study was to detect the expression level of miR-200c in NSCLC, and to analyze its association with clinicopathological factors and patient prognosis. The present study determined the expression levels of miR-200c in 110 tumor samples collected from patients diagnosed with NSCLC who underwent complete tumor resection with regional lymph node dissection, as assessed by reverse transcription-quantitative polymerase chain reaction. The association between the expression level of miR-200c and clinicopathological features and patient prognosis was also analyzed. The results showed that miR-200c overexpression was detected in 66 of the 110 cases and was significantly associated with positive lymph node metastasis (P<0.001). Univariate survival analysis demonstrated that high miR-200c expression, positive lymph node metastasis and advanced Tumor-Node-Metastasis (TNM) classification stage significantly predicted decreased 5-year disease-free survival rates (all P<0.05) and poor 5-year overall survival rates (all P<0.01), respectively. The results of multivariate Cox regression analysis showed that TNM stage and miR-200c expression retained its significance as an independent prognostic factor for unfavorable 5-year disease-free survival rates (P<0.05) and poor 5-year overall survival rates (P<0.01). The present findings suggest that miR-200c overexpression is significantly associated with poor survival rates in NSCLC and that miR-200c could play an oncogenic role. miR-200c may have clinical potential as a promising prognostic predictor for patients with NSCLC.

Entities:  

Keywords:  disease-free survival; microRNA-200c; non-small cell lung cancer; overall survival; prognosis

Year:  2017        PMID: 28943946      PMCID: PMC5604169          DOI: 10.3892/ol.2017.6667

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer.

Authors:  Tao Bai; Dao-Song Dong; Ling Pei
Journal:  Oncol Rep       Date:  2014-03-14       Impact factor: 3.906

3.  Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness.

Authors:  Ying Xie; Cody J Wehrkamp; Jing Li; Yan Wang; Yazhe Wang; Justin L Mott; David Oupický
Journal:  Mol Pharm       Date:  2016-02-08       Impact factor: 4.939

Review 4.  Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment.

Authors:  Bing Feng; Kai Zhang; Rui Wang; Longbang Chen
Journal:  Clin Sci (Lond)       Date:  2015-05-01       Impact factor: 6.124

5.  MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.

Authors:  H Rajabi; M Alam; H Takahashi; A Kharbanda; M Guha; R Ahmad; D Kufe
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

6.  Role of miR-200c/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma.

Authors:  Shunji Tamagawa; Levent Bekir Beder; Muneki Hotomi; Mehmet Gunduz; Kazuya Yata; Reidar Grenman; Noboru Yamanaka
Journal:  Int J Mol Med       Date:  2014-01-14       Impact factor: 4.101

7.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Authors:  Manav Korpal; Brian J Ell; Francesca M Buffa; Toni Ibrahim; Mario A Blanco; Toni Celià-Terrassa; Laura Mercatali; Zia Khan; Hani Goodarzi; Yuling Hua; Yong Wei; Guohong Hu; Benjamin A Garcia; Jiannis Ragoussis; Dino Amadori; Adrian L Harris; Yibin Kang
Journal:  Nat Med       Date:  2011-08-07       Impact factor: 53.440

8.  A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.

Authors:  Manjari Dimri; Mingu Kang; Goberdhan P Dimri
Journal:  Oncotarget       Date:  2016-06-14

9.  miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma.

Authors:  Rut Tejero; Alfons Navarro; Marc Campayo; Nuria Viñolas; Ramon M Marrades; Anna Cordeiro; Marc Ruíz-Martínez; Sandra Santasusagna; Laureano Molins; Josep Ramirez; Mariano Monzó
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer.

Authors:  Ching-Feng Wu; Jui-Ying Fu; Chi-Ju Yeh; Yun-Hen Liu; Ming-Ju Hsieh; Yi-Cheng Wu; Ching-Yang Wu; Ying-Huang Tsai; Wen-Chi Chou
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

View more
  9 in total

1.  High-Resolution In Vivo Identification of miRNA Targets by Halo-Enhanced Ago2 Pull-Down.

Authors:  Xiaoyi Li; Yuri Pritykin; Carla P Concepcion; Yuheng Lu; Gaspare La Rocca; Minsi Zhang; Bryan King; Peter J Cook; Yu Wah Au; Olesja Popow; Joao A Paulo; Hannah G Otis; Chiara Mastroleo; Paul Ogrodowski; Ryan Schreiner; Kevin M Haigis; Doron Betel; Christina S Leslie; Andrea Ventura
Journal:  Mol Cell       Date:  2020-06-03       Impact factor: 17.970

2.  Recent biomedical advances enabled by HaloTag technology.

Authors:  Weiyu Chen; Muhsin H Younis; Zhongkuo Zhao; Weibo Cai
Journal:  Biocell       Date:  2022-04-22       Impact factor: 1.110

Review 3.  A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.

Authors:  Lin Chen; Yong Wang; Fen Liu; Liyao Xu; Feifei Peng; Ning Zhao; Biqi Fu; Zijie Zhu; Yu Shi; Jiansheng Liu; Renrui Wu; Chen Wang; Shengmin Yao; Yong Li
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

4.  Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.

Authors:  Cheng Zhang; Chun-Dong Zhang; Ming-Hui Ma; Dong-Qiu Dai
Journal:  World J Gastroenterol       Date:  2018-03-21       Impact factor: 5.742

5.  Correlation between miR-200 Family Overexpression and Cancer Prognosis.

Authors:  Wen Liu; Kaiping Zhang; Pengfei Wei; Yue Hu; Yaqin Peng; Xiang Fang; Guoping He; Limin Wu; Min Chao; Jing Wang
Journal:  Dis Markers       Date:  2018-07-04       Impact factor: 3.434

Review 6.  The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers.

Authors:  Ilaria Cavallari; Francesco Ciccarese; Evgeniya Sharova; Loredana Urso; Vittoria Raimondi; Micol Silic-Benussi; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Cancers (Basel)       Date:  2021-11-23       Impact factor: 6.639

7.  MicroRNA-200a-3p and GATA6 are abnormally expressed in patients with non-small cell lung cancer and exhibit high clinical diagnostic efficacy.

Authors:  Jie Yu; Xinyun He; Chunju Fang; Haixia Wu; Lei Hu; Yingbo Xue
Journal:  Exp Ther Med       Date:  2022-02-15       Impact factor: 2.447

8.  MiR-942-3p as a Potential Prognostic Marker of Gastric Cancer Associated with AR and MAPK/ERK Signaling Pathway.

Authors:  Wenjia Liu; Nanjiao Ying; Xin Rao; Xiaodong Chen
Journal:  Curr Issues Mol Biol       Date:  2022-08-24       Impact factor: 2.976

9.  A Five-microRNA Signature as Prognostic Biomarker in Colorectal Cancer by Bioinformatics Analysis.

Authors:  Guodong Yang; Yujiao Zhang; Jiyuan Yang
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.